SANUWAVE Q1 revenue up 53% to $5.8M; operating loss narrows to $1.1M; reaffirms FY 2024 growth guidance of 50%

SANUWAVE Health, Inc.

2024-Q1 EPS reported $0.00 revenue$5,786,000

Revenue $5.8M (+53% YoY); gross margin 73% (+600bps); UltraMist consumables revenue $4.1M (+64%).
Operating loss $1.1M vs $2.0M in Q1 2023; net loss $4.5M includes $3.9M non-cash derivative charge.
Adjusted EBITDA loss improved to $59K from $1.8M loss YoY.
Guidance: Q2 2024 revenue growth 45-55% YoY; FY 2024 revenue growth of 50% reiterated.
Sold 43 UltraMist systems in Q1 (up from 28 in Q1 2023, down from 79 in Q4 2023).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANUWAVE Health, Inc. reported first quarter ended March 31, 2024 results: revenue $5.8 million, net income $4.5 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $5.8 million
Net income: $4.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 ef20028815_99-1.htm EXHIBIT 99.1 Exhibit 99.1 SANUWAVE Announces Q1 FY2024 Financial Results Q1 2024 revenues were $5.8 million, up 53% from Q1 2023 Q1 2024 gross margin was 73%, up 600bp from Q1 2023 Operating loss was $1.1 million for Q1 2024 compared to $2.0 million for Q1 2023 Company provides

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-025326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.